BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22064355)

  • 1. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications.
    Damm F; Thol F; Kosmider O; Kade S; Löffeld P; Dreyfus F; Stamatoullas-Bastard A; Tanguy-Schmidt A; Beyne-Rauzy O; de Botton S; Guerci-Bresler A; Göhring G; Schlegelberger B; Ganser A; Bernard OA; Fontenay M; Heuser M
    Leukemia; 2012 May; 26(5):1137-40. PubMed ID: 22064355
    [No Abstract]   [Full Text] [Related]  

  • 2. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
    Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
    Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution.
    Lin CC; Hou HA; Chou WC; Kuo YY; Wu SJ; Liu CY; Chen CY; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Hsu SC; Ko BS; Tsay W; Chen YC; Tien HF
    Am J Hematol; 2014 Aug; 89(8):E109-15. PubMed ID: 24723457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a high-resolution melting analysis for the detection of the SF3B1 mutations.
    Yang J; Qian J; Lin J; Yang XF; Qian W; Chen Q; Yao DM; Wang CZ; Chen XX; Xiao GF; Ma YJ
    Genet Test Mol Biomarkers; 2013 Apr; 17(4):342-7. PubMed ID: 23390883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.
    Malcovati L; Karimi M; Papaemmanuil E; Ambaglio I; Jädersten M; Jansson M; Elena C; Gallì A; Walldin G; Della Porta MG; Raaschou-Jensen K; Travaglino E; Kallenbach K; Pietra D; Ljungström V; Conte S; Boveri E; Invernizzi R; Rosenquist R; Campbell PJ; Cazzola M; Hellström Lindberg E
    Blood; 2015 Jul; 126(2):233-41. PubMed ID: 25957392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Gene mutation and myelodysplastic syndromes with ring sideroblast excess].
    Meng FK; Huang LF; Zhou JF; Sun HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):1088-90. PubMed ID: 23998618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value.
    Patnaik MM; Lasho TL; Hodnefield JM; Knudson RA; Ketterling RP; Garcia-Manero G; Steensma DP; Pardanani A; Hanson CA; Tefferi A
    Blood; 2012 Jan; 119(2):569-72. PubMed ID: 22096241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
    Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
    BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of SF3B1 mutations in Korean patients with myelodysplastic syndromes and myelodysplasia/myeloproliferative neoplasms with ring sideroblasts.
    Seo JY; Lee KO; Kim SH; Kim K; Jung CW; Jang JH; Kim HJ
    Ann Hematol; 2014 Apr; 93(4):603-8. PubMed ID: 24141330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
    Malcovati L; Papaemmanuil E; Bowen DT; Boultwood J; Della Porta MG; Pascutto C; Travaglino E; Groves MJ; Godfrey AL; Ambaglio I; Gallì A; Da Vià MC; Conte S; Tauro S; Keenan N; Hyslop A; Hinton J; Mudie LJ; Wainscoat JS; Futreal PA; Stratton MR; Campbell PJ; Hellström-Lindberg E; Cazzola M;
    Blood; 2011 Dec; 118(24):6239-46. PubMed ID: 21998214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Deregulated splicing machinery in myelodysplastic syndromes].
    Ogawa S
    Rinsho Ketsueki; 2012 May; 53(5):493-6. PubMed ID: 22728550
    [No Abstract]   [Full Text] [Related]  

  • 12. A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages.
    Gentien D; Kosmider O; Nguyen-Khac F; Albaud B; Rapinat A; Dumont AG; Damm F; Popova T; Marais R; Fontenay M; Roman-Roman S; Bernard OA; Stern MH
    Leukemia; 2014 Jun; 28(6):1355-7. PubMed ID: 24434863
    [No Abstract]   [Full Text] [Related]  

  • 13. SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype.
    Visconte V; Tabarroki A; Rogers HJ; Hasrouni E; Traina F; Makishima H; Hamilton BK; Liu Y; O'Keefe C; Lichtin A; Horwitz L; Sekeres MA; Hsieh FH; Tiu RV
    Haematologica; 2013 Sep; 98(9):e105-7. PubMed ID: 23831919
    [No Abstract]   [Full Text] [Related]  

  • 14. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance.
    Patnaik MM; Lasho TL; Finke CM; Hanson CA; Hodnefield JM; Knudson RA; Ketterling RP; Pardanani A; Tefferi A
    Am J Hematol; 2013 Mar; 88(3):201-6. PubMed ID: 23335386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SF3b1 mutations associated with myelodysplastic syndromes alter the fidelity of branchsite selection in yeast.
    Carrocci TJ; Zoerner DM; Paulson JC; Hoskins AA
    Nucleic Acids Res; 2017 May; 45(8):4837-4852. PubMed ID: 28062854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. It dices, it splices!
    Klimek VM
    Blood; 2011 Dec; 118(24):6237-8. PubMed ID: 22161850
    [No Abstract]   [Full Text] [Related]  

  • 17. Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1.
    Ambaglio I; Malcovati L; Papaemmanuil E; Laarakkers CM; Della Porta MG; Gallì A; Da Vià MC; Bono E; Ubezio M; Travaglino E; Albertini R; Campbell PJ; Swinkels DW; Cazzola M
    Haematologica; 2013 Mar; 98(3):420-3. PubMed ID: 23300182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical importance of SF3B1 mutations in Chinese with myelodysplastic syndromes with ring sideroblasts.
    Cui R; Gale RP; Xu Z; Qin T; Fang L; Zhang H; Pan L; Zhang Y; Xiao Z
    Leuk Res; 2012 Nov; 36(11):1428-33. PubMed ID: 22921018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.
    Damm F; Kosmider O; Gelsi-Boyer V; Renneville A; Carbuccia N; Hidalgo-Curtis C; Della Valle V; Couronné L; Scourzic L; Chesnais V; Guerci-Bresler A; Slama B; Beyne-Rauzy O; Schmidt-Tanguy A; Stamatoullas-Bastard A; Dreyfus F; Prébet T; de Botton S; Vey N; Morgan MA; Cross NC; Preudhomme C; Birnbaum D; Bernard OA; Fontenay M;
    Blood; 2012 Apr; 119(14):3211-8. PubMed ID: 22343920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML.
    Hirabayashi S; Flotho C; Moetter J; Heuser M; Hasle H; Gruhn B; Klingebiel T; Thol F; Schlegelberger B; Baumann I; Strahm B; Stary J; Locatelli F; Zecca M; Bergstraesser E; Dworzak M; van den Heuvel-Eibrink MM; De Moerloose B; Ogawa S; Niemeyer CM; Wlodarski MW;
    Blood; 2012 Mar; 119(11):e96-9. PubMed ID: 22238327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.